XenoPort Inc. signed GlaxoSmithKline plc as a co-development and commercialization partner for XP13512, its lead product candidate in late-stage development for restless legs syndrome (RLS) and neuropathic pain. The deal could total up to $640 million in up-front and milestone payments. (BioWorld Today) Read More
